DK2852399T3 - Ledgf-peptider og formuleringer deraf til behandling af degenerative lidelser - Google Patents
Ledgf-peptider og formuleringer deraf til behandling af degenerative lidelser Download PDFInfo
- Publication number
- DK2852399T3 DK2852399T3 DK13794410.4T DK13794410T DK2852399T3 DK 2852399 T3 DK2852399 T3 DK 2852399T3 DK 13794410 T DK13794410 T DK 13794410T DK 2852399 T3 DK2852399 T3 DK 2852399T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulas
- treatment
- degenerative disorders
- ledgf peptides
- ledgf
- Prior art date
Links
- 230000003412 degenerative effect Effects 0.000 title 1
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649847P | 2012-05-21 | 2012-05-21 | |
| PCT/US2012/065620 WO2013074988A1 (en) | 2011-11-17 | 2012-11-16 | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
| PCT/US2013/042074 WO2013177198A1 (en) | 2012-05-21 | 2013-05-21 | Ledgf peptides and formulations thereof for treatment of degenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2852399T3 true DK2852399T3 (da) | 2020-05-04 |
Family
ID=49624295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13794410.4T DK2852399T3 (da) | 2012-05-21 | 2013-05-21 | Ledgf-peptider og formuleringer deraf til behandling af degenerative lidelser |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9526760B2 (https=) |
| EP (1) | EP2852399B1 (https=) |
| JP (2) | JP6632376B2 (https=) |
| CN (2) | CN110054677A (https=) |
| AU (1) | AU2013266468B2 (https=) |
| BR (1) | BR112014028951A8 (https=) |
| CA (1) | CA2873771A1 (https=) |
| DK (1) | DK2852399T3 (https=) |
| ES (1) | ES2791251T3 (https=) |
| IN (1) | IN2014MN02461A (https=) |
| RU (1) | RU2617964C2 (https=) |
| WO (1) | WO2013177198A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014028951A8 (pt) * | 2012-05-21 | 2021-09-14 | Univ Colorado Regents | Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
| JP7549575B2 (ja) * | 2018-06-22 | 2024-09-11 | ビオラリクス ベー．フェー． | 経口投与用生物学的ポリマーの製剤 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
| US4469689A (en) | 1983-03-30 | 1984-09-04 | The Upjohn Company | Sulfonate containing ester prodrugs of corticosteroids |
| US6750052B1 (en) | 1997-07-23 | 2004-06-15 | The Brigham And Women's Hospital, Inc. | Lens epithelial cell derived growth factor |
| US7708915B2 (en) * | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040157810A1 (en) | 2002-08-23 | 2004-08-12 | Teicher Martin H. | Corticosteroid conjugates and uses thereof |
| US7514233B2 (en) | 2002-09-26 | 2009-04-07 | K.U. Leuven Research & Development | Integrase cofactor |
| US20040253606A1 (en) * | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| US20060166879A1 (en) | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| WO2004063355A2 (en) * | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| EP1774043A4 (en) * | 2004-05-28 | 2009-09-02 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER |
| EP1971288B1 (en) | 2005-12-30 | 2013-02-13 | Neurotech USA, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| EP2520935A3 (en) * | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008053478A2 (en) * | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| US8168393B2 (en) * | 2007-02-16 | 2012-05-01 | The Brigham And Women's Hospital, Inc. | Compositions and methods for diagnosing tumors using LEDGF/p75 |
| AU2009262670B2 (en) * | 2008-06-26 | 2013-06-20 | Zevra Denmark A/S | Use of Hsp70 as a regulator of enzymatic activity |
| GB0812742D0 (en) * | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| US10234453B2 (en) * | 2011-07-01 | 2019-03-19 | Inova Diagnostics, Inc. | Method for increasing specificity of diagnostic tests for autoimmune diseases |
| BR112014028951A8 (pt) * | 2012-05-21 | 2021-09-14 | Univ Colorado Regents | Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor |
-
2013
- 2013-05-21 BR BR112014028951A patent/BR112014028951A8/pt not_active IP Right Cessation
- 2013-05-21 CN CN201811628163.9A patent/CN110054677A/zh active Pending
- 2013-05-21 AU AU2013266468A patent/AU2013266468B2/en active Active
- 2013-05-21 US US14/402,426 patent/US9526760B2/en active Active
- 2013-05-21 RU RU2014151603A patent/RU2617964C2/ru active
- 2013-05-21 WO PCT/US2013/042074 patent/WO2013177198A1/en not_active Ceased
- 2013-05-21 DK DK13794410.4T patent/DK2852399T3/da active
- 2013-05-21 IN IN2461MUN2014 patent/IN2014MN02461A/en unknown
- 2013-05-21 EP EP13794410.4A patent/EP2852399B1/en active Active
- 2013-05-21 CN CN201380038504.6A patent/CN104470534A/zh active Pending
- 2013-05-21 CA CA2873771A patent/CA2873771A1/en not_active Abandoned
- 2013-05-21 ES ES13794410T patent/ES2791251T3/es active Active
- 2013-05-21 JP JP2015514127A patent/JP6632376B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-10 US US15/348,970 patent/US10221226B2/en active Active
-
2018
- 2018-05-23 JP JP2018098420A patent/JP2018172386A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2791251T3 (es) | 2020-11-03 |
| CN104470534A (zh) | 2015-03-25 |
| CA2873771A1 (en) | 2013-11-28 |
| AU2013266468A1 (en) | 2014-12-18 |
| US10221226B2 (en) | 2019-03-05 |
| AU2013266468B2 (en) | 2017-11-09 |
| JP2015519343A (ja) | 2015-07-09 |
| BR112014028951A8 (pt) | 2021-09-14 |
| JP2018172386A (ja) | 2018-11-08 |
| CN110054677A (zh) | 2019-07-26 |
| BR112014028951A2 (pt) | 2017-07-25 |
| US20170129929A1 (en) | 2017-05-11 |
| US20150147404A1 (en) | 2015-05-28 |
| IN2014MN02461A (https=) | 2015-07-10 |
| WO2013177198A1 (en) | 2013-11-28 |
| RU2617964C2 (ru) | 2017-04-28 |
| JP6632376B2 (ja) | 2020-01-22 |
| EP2852399A1 (en) | 2015-04-01 |
| RU2014151603A (ru) | 2016-07-10 |
| US9526760B2 (en) | 2016-12-27 |
| EP2852399A4 (en) | 2016-03-23 |
| EP2852399B1 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2794604T3 (da) | Hidtil ukendte dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af inflammatoriske lidelse | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK2838917T3 (da) | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK2919923T3 (da) | Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK2882496T3 (da) | Behandling og diagnosticering af melanom | |
| DK3269716T3 (da) | Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser | |
| DK2704703T3 (da) | Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf | |
| DK3039146T3 (da) | Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose | |
| DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| DK3363901T3 (da) | Sammensætninger og fremgangsmåder til præcis identificering af mutationer | |
| DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
| DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
| DK3685848T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK2701693T3 (da) | Tapentadol til hindring og behandling af depression og angst |